Logo
HYMOVIS ONE® is a sterile, hydrogel manufactured with HYADD®4: (hexadecylamide of highly purified natural sodium hyaluronate obtained by bacterial fermentation)4.
Thanks to the high viscosity and elasticity given by the hexadecylamide of sodium hyaluronate, HYMOVIS ONE® improves the lubricating and shock absorbing function of synovial fluid, protecting cartilage and soft tissues against mechanical injuries4.
These properties, together with the prolonged residence time in the articular joints, enable HYMOVIS ONE® to relieve pain and to improve joint function, in mild or moderate hip and knee osteoarthritis of any origin, up to six-twelve months2

why monoinjection?

Reduces visits1 and enhances compliance2

Rapid and minimally invasive procedure 2

Rapid and long lasting response 2

HYADD®4

HYADD®4 is an innovative hyaluronic acid hydrogel developed by Fidia Farmaceutici, marketed under the brand name HYMOVIS®. This advanced formulation features a unique hexadecylamide derivative of hyaluronic acid, enhancing its viscoelastic properties and prolonging its residence time in the joint

HYADD®4 is designed to provide effective viscosupplementation, improving joint lubrication and cushioning, which can significantly alleviate pain and improve mobility in still very active patients with osteoarthritis.

Clinical studies have demonstrated its efficacy in reducing symptoms and enhancing the quality of life for high demand patients with OA.

The hydrogel is administered via intra-articular injection, offering a promising alternative for those who have not responded well to conventional treatments.

WHAT IS HYMOVIS ONE?®

HYDROGEL

4th generation intra-articular HA based
product MD3

HYADD®4

Hexadecylamide of highly purified natural sodium hyaluronate obtained by bacterial fermentation4

MO.RE. (MObile REticulum) TECHNOLOGY

A network stabilized by reversible hydrophobic interactions, conferring high viscoelasticity and stability to 500-730 kDa MW HA derivative3

Composition

HYADD®4:
(hexadecylamide of highly purified natural sodium hyaluronate obtained by bacterial fermentation)4
32 mg/4mL

Available
Presentation

Box containing 1
pre-filled syringe4

Indications

HYMOVIS ONE® is indicated for the treatment of patients affected by mild or moderate osteoarthritis of the knee and hip.
The device is indicated for the treatment of OA of any origin4

Dosage &
Administration

  • HYMOVIS ONE® is intended in monoinjection regimen for intra-articular injection only4

PRODUCT PORTFOLIO

VISCOSUPPLEMENTATION

Medical Devices CE0459.
Read the instructions for use carefully.
References:
1. Gavin C, et al. One-Year, Efficacy and Safety Open Label Study, with a Single Injection of a New Hyaluronan for Knee OA: The SOYA Trial. Journal of Pain Research 2021:14 2229–2237
2. Bernetti A, et al. New Viscoelastic Hydrogel Hymovis® MO.RE. Single Intra-articular Injection for the Treatment of Knee Osteoarthritis in Sportsmen: Safety and Efficacy Study Results. Front. Pharmacol. 12:673988. doi: 10.3389/fphar.2021.673988.
3. Finelli I, et al. A new viscosupplement based on partially hydrophobic hyaluronic acid: A comparative study. Biorheology 48 (2011) 263–275.
4. Hymovis One® IFU

You are about to leave fidiajointcare.com

All information you are about to see is related to a specific selected market, including the products’ portfolio, and therefore comply to different local regulations.

Proceed